Photo via Washington Examiner

American patients shouldn’t foot the bill for the world’s medicines

Read the original at Washington Examiner ↗
Cite

Wenstrup, R. B. (2026, September 17). American patients shouldn’t foot the bill for the world’s medicines. Washington Examiner. https://www.washingtonexaminer.com/op-eds/4730147/lower-prescription-drug-costs-foreign-trade/

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Washington Examiner · collected 2026-09-17 · by Rep. Brad Wenstrup

Quick Summary

Voters are increasingly concerned about the affordability of prescription drugs, with healthcare costs ranking as their top economic worry. Republicans argue that they have effective solutions like transparency in pharmacy benefit manager practices and free-market competition rather than government price-setting. The article highlights Trump’s Most-Favored-Nation negotiations and the proposed USTRx Act to ensure foreign governments pay a fair share for pharmaceutical innovation, countering the current situation where American patients bear an excessive financial burden while other countries leverage steep discounts from American drugmakers.
Written by AI on 2026-09-17, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Voters are increasingly worried about healthcare costs, with prescription drug affordability being a top concern. In November, Democrats had a 12-point lead over Republicans regarding voters' trust in handling healthcare issues. Republican Representative Brad Wenstrup argues that his party's approach of transparency and free-market competition could help close this gap. He cites the Better Deals and Lower Prices Act, signed by President Donald Trump, which required pharmacy benefit managers to disclose rebates and fees previously hidden from patients and employers, aiming to reduce drug costs. Republicans advocate for measures like this as an alternative to government-imposed price controls, which they argue are exploited by other countries to lower their own drug prices at the expense of American consumers.

Written for “Global Medicine Costs” on 2026-11-02, grounded in this article and the 0 other(s) covering the same event.

Story

📰 Global Medicine Costs
Politics · 1 article(s) covering the same event.

Compared with similar articles

This article reads leans strongly right and hedges 0% of its claims. Each row says how that neighbour differs.
The Dispatch
⚖️ Leans strongly right Hedges 8 of 111 claims Outlet record 61/100
“Both articles discuss healthcare costs and affordability concerns among American voters, but they are not reporting on the same specific incident or occurrence.”
Semafor
Hedges 1 of 6 claims Outlet record 59/100
“The articles describe different aspects of the issue: one discusses voter concerns and trust in political parties regarding healthcare costs, while the other reports on a White House announcement about drug pricing progress.”
Washington Examiner
⚖️ Leans left further left than this Hedges 0 of 10 claims Outlet record 70/100
“Article A discusses voter concerns about healthcare costs and drug affordability leading up to an election, while Article B reports on a specific announcement by President Trump regarding Medicaid drug prices negotiated by his administration.”
NBC News
Outlet record 60/100
“The articles discuss related topics but describe different events and perspectives on healthcare costs and political trust.”
Washington Examiner
⚖️ Leans strongly left further left than this Hedges 1 of 29 claims Outlet record 70/100
“The articles discuss different aspects of prescription drug costs and blame, with Article A focusing on voter concerns and political implications, while Article B targets PBMs and insurers as the cause of rising costs.”
Washington Examiner
⚖️ Leans strongly right Hedges 1 of 26 claims Outlet record 70/100
“The articles discuss different aspects of healthcare and political campaigning without describing the same specific incident.”
Fox News
⚖️ Leans left further left than this Hedges 1 of 60 claims Outlet record 69/100
“The articles cover related topics (voter concerns about healthcare costs) but describe different specific events: one is a Fox News poll surveying voter opinions, and the other discusses policy perspectives on addressing those concerns.”
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
29
sentences that state something as happening or true
Uncertain
0%
0 of 29 hedged ("reportedly", "may", "according to")
Leaning
Leans strongly right
of the writing, not the subject · beta estimate
Publisher signals
70/100
Washington Examiner's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Politics
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-17 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Washington Examiner · 3903 article(s) · 7 correction(s) detected
Running correction rate · 7 correction(s)

Who wrote this

Rep. Brad Wenstrup
1 article(s) here · 1 carrying a prediction
🔮 Wealthy governments in Europe and elsewhere impose price controls on their own markets and squeeze steep discounts out of American drugmakers, knowing the U.S. market will make up the difference by paying more.
The only article under this byline in the corpus.

Topics

America American Americans Republicans Washington

Subjects

American NORP · 7× America GPE · 3× Republicans NORP · 3× Americans NORP · 2× Ohio GPE · 2× U.S. GPE · 2× Washington GPE · 2× Democrats NORP · 1× Donald Trump PERSON · 1× Kaiser Family Foundation ORG · 1×

Narrative

For example, the Better Deals and Lower Prices Act, signed into law by President Donald Trump, forced pharmacy benefit managers, the middlemen who have long operated in the dark, to give employers and patients real visibility into the rebates and fees that have quietly driven up the price of prescriptions.
framing: assertive · carried by 1 article(s) · first seen 2026-09-17
🔮 Wealthy governments in Europe and elsewhere impose price controls on their own markets and squeeze steep discounts out of American drugmakers, knowing the U.S. market will make up the difference by paying more.
2026-09-17 · Washington Examiner
American patients shouldn’t foot the bill for the world’s medicines · assertive framing

Claims (29 extracted, 0 hedged)

Heading into November, voters rank healthcare costs as their single biggest economic worry. asserted
voters → head → worry
For the first time since Kaiser Family Foundation began tracking the question in 2018, a majority now say they’re specifically anxious about affording their prescriptions. asserted
they → track → prescriptions
And right now, voters trust Democrats more than Republicans to do something about it, by roughly 12 points, and by a similar margin on drug affordability specifically. asserted
voters → trust → affordability
Republicans can close that gap. asserted
Republicans → close → gap
We have the ideas that actually work, such as transparency and free-market competition rather than Washington price-setting, and trade leverage instead of surrendering to foreign governments that have spent decades exploiting American drug innovation. asserted
that → have → innovation
I’ve made that case from a medical practice in Ohio and from battlefields abroad, and I’ve watched it hold up under pressure: Lowering costs for American families requires exposing who’s actually driving costs up, at home and abroad. asserted
who → make → home
For example, the Better Deals and Lower Prices Act, signed into law by President Donald Trump, forced pharmacy benefit managers, the middlemen who have long operated in the dark, to give employers and patients real visibility into the rebates and fees that have quietly driven up the price of prescriptions. asserted
that → sign → prescriptions
The bipartisan No Surprises Act, on the other hand, mandates payment disputes between insurers and doctors be settled by a neutral arbiter weighing real market factors, not by Washington setting a fixed rate. asserted
Washington → mandate → rate
Both efforts rest on the same principle: hold the system accountable and attack what’s actually driving up costs while maintaining America’s healthcare leadership. asserted
what → rest → leadership
Now America is taking on another cost driver, one that reaches past our own borders. asserted
that → take → borders
For years, American patients have shouldered a disproportionate share of the cost of the innovation the entire developed world relies on. asserted
world → shoulder → innovation
Wealthy governments in Europe and elsewhere impose price controls on their own markets and squeeze steep discounts out of American drugmakers, knowing the U.S. market will make up the difference by paying more. asserted
market → impose → more
Trump’s most-favored-nation negotiations are chipping away at that imbalance by lowering what Americans pay. asserted
Americans → favor → what
But that’s only one side of the ledger. asserted
that → ’ → ledger
If foreign governments respond by driving their own prices down even further, the money that funds tomorrow’s cures doesn’t shift to America; it just disappears. asserted
it → respond → America
Americans should pay less while foreign governments pay their fair share, too. asserted
governments → pay → share
The USTRx Act can make a difference. asserted
Act → make → difference
The bill would create a chief pharmaceutical trade negotiator inside the Office of the U.S. Trade Representative to identify foreign price controls and market barriers that disadvantage American patients and innovation. asserted
that → create → patients
Our negotiators would have real leverage to make foreign governments pay their share. asserted
governments → have → share
Germany is the case in point happening right now. asserted
Germany → happen → point
Berlin is pushing a new rebate scheme that would squeeze American drugmakers further. asserted
that → push → drugmakers
That’s precisely the kind of quiet cost-shifting the USTRx Act is built to confront before foreign schemes get locked in. asserted
schemes → ’ → shifting
Republicans leading in this effort can increase public trust. asserted
Republicans → lead → trust
A McLaughlin & Associates poll found 72% of voters agree it’s time to make other countries pay their fair share for prescription drugs. asserted
countries → find → drugs
Voters want Congress to act. asserted
Congress → want → ?
Trust grows not with better talking points but with results, such as exposing pharmacy middlemen, holding insurers accountable, and getting foreign governments to pay their share. asserted
governments → grow → share
I’ve left elected office, but my fight for patients doesn’t stay behind. asserted
fight → leave → patients
The world benefits from American medicine. asserted
world → benefit → medicine
It’s time the world paid for it. asserted
world → ’ → it
💬Give feedback
🕘History 🎫Support